EX-99.2 4 y88382exv99w2.txt SUPPLEMENTAL INFORMATION Exhibit 99.2 MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES SECOND QUARTER 2003 NET PRODUCT SALES DETAIL
---------------------------------------------------------------- 2Q `03 vs. 2Q `02 ---------------------------------------------------------------- TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN ------------------------------------ PRODUCT % CHG $ % CHG $ % CHG $ ---------------------------------------------------------------------------------------------------- AGGRASTAT -9% 26 -49% 6 22% 19 ---------------------------------------------------------------------------------------------------- ARCOXIA * 16 N/M - * 16 ---------------------------------------------------------------------------------------------------- CANCIDAS * 62 * 36 * 26 ---------------------------------------------------------------------------------------------------- COZAAR / HYZAAR 3% 543 -33% 149 28% 394 ---------------------------------------------------------------------------------------------------- CRIXIVAN/STOCRIN 0% 82 -25% 25 18% 57 ---------------------------------------------------------------------------------------------------- EMEND * 15 * 15 N/M - ---------------------------------------------------------------------------------------------------- FOSAMAX -9% 535 -40% 251 71% 284 ---------------------------------------------------------------------------------------------------- INVANZ * 8 * 7 * 2 ---------------------------------------------------------------------------------------------------- MAXALT -7% 52 -28% 27 39% 24 ---------------------------------------------------------------------------------------------------- PRIMAXIN 3% 146 -29% 33 18% 113 ---------------------------------------------------------------------------------------------------- PRINIVIL / PRINZIDE -80% 38 -88% 21 -5% 17 ---------------------------------------------------------------------------------------------------- PROPECIA -3% 51 -17% 21 11% 30 ---------------------------------------------------------------------------------------------------- PROSCAR 53% 174 83% 87 32% 88 ---------------------------------------------------------------------------------------------------- SINGULAIR 89% 427 * 272 59% 156 ---------------------------------------------------------------------------------------------------- TIMOPTIC/TIMOPTIC XE -1% 43 -18% 5 2% 37 ---------------------------------------------------------------------------------------------------- TRUSOPT/COSOPT 8% 123 -8% 52 23% 72 ---------------------------------------------------------------------------------------------------- VASOTEC / VASERETIC -2% 201 50% (4) -4% 205 ---------------------------------------------------------------------------------------------------- VIOXX 1% 801 -7% 543 24% 258 ---------------------------------------------------------------------------------------------------- ZOCOR 3% 1,242 18% 773 -14% 468 ---------------------------------------------------------------------------------------------------- HEPATITIS VACCINES -18% 52 -25% 43 38% 9 ---------------------------------------------------------------------------------------------------- VIRAL VACCINES -31% 134 -35% 125 * 10 ---------------------------------------------------------------------------------------------------- OTHER VACCINES -19% 50 -21% 39 -11% 11 ----------------------------------------------------------------------------------------------------
* > 100% N/M - Not Meaningful TOTAL SALES: VOLUME, PRICE, EXCHANGE
---------------------------------------------------- 2Q `03 % CHG. VOL PX FX ---------------------------------------------------------------------------------------- TOTAL SALES $13,281 4% -4 6 2 ------- -- --- -- -- Total Pharmaceutical Sales 5,546 7% 2 0 5 ------- -- --- -- -- U.S. 3,235 2% 1 1 0 Foreign 2,312 14% 2 -1 13 ------------------------------ Other Medco Sales 7,735 2% ----------------------------------------------------------
Exhibit 99.2 MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES SIX MONTHS YEAR TO DATE 2003 NET PRODUCT SALES DETAIL
------------------------------------------------------------------ JUNE YTD `03 vs. JUNE YTD `02 ------------------------------------------------------------------ TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN ---------------------------------- PRODUCT % CHG $ % CHG $ % CHG $ ---------------------------------------------------------------------------------------------------- AGGRASTAT -6% 48 -58% 9 33% 39 ---------------------------------------------------------------------------------------------------- ARCOXIA * 28 N/M - * 28 ---------------------------------------------------------------------------------------------------- CANCIDAS * 108 * 62 * 46 ---------------------------------------------------------------------------------------------------- COZAAR / HYZAAR 24% 1,187 9% 446 36% 741 ---------------------------------------------------------------------------------------------------- CRIXIVAN/STOCRIN 11% 166 17% 64 8% 102 ---------------------------------------------------------------------------------------------------- EMEND * 15 * 15 N/M - ---------------------------------------------------------------------------------------------------- FOSAMAX 23% 1,348 4% 836 72% 512 ---------------------------------------------------------------------------------------------------- INVANZ * 14 * 11 * 3 ---------------------------------------------------------------------------------------------------- MAXALT 5% 131 -5% 87 33% 44 ---------------------------------------------------------------------------------------------------- PRIMAXIN 18% 309 31% 94 13% 215 ---------------------------------------------------------------------------------------------------- PRINIVIL / PRINZIDE -81% 74 -88% 43 -13% 31 ---------------------------------------------------------------------------------------------------- PROPECIA 16% 117 21% 58 12% 59 ---------------------------------------------------------------------------------------------------- PROSCAR 36% 313 54% 151 23% 162 ---------------------------------------------------------------------------------------------------- SINGULAIR 40% 901 34% 613 54% 288 ---------------------------------------------------------------------------------------------------- TIMOPTIC/TIMOPTIC XE -3% 79 -44% 7 4% 71 ---------------------------------------------------------------------------------------------------- TRUSOPT/COSOPT 15% 230 10% 98 19% 133 ---------------------------------------------------------------------------------------------------- VASOTEC / VASERETIC -6% 369 * (8) -2% 377 ---------------------------------------------------------------------------------------------------- VIOXX -4% 1,328 -15% 861 22% 467 ---------------------------------------------------------------------------------------------------- ZOCOR 5% 2,491 11% 1,486 -2% 1,005 ---------------------------------------------------------------------------------------------------- HEPATITIS VACCINES 13% 117 6% 98 69% 20 ---------------------------------------------------------------------------------------------------- VIRAL VACCINES -11% 252 -15% 234 * 18 ---------------------------------------------------------------------------------------------------- OTHER VACCINES 22% 109 21% 85 25% 24 ----------------------------------------------------------------------------------------------------
* > 100% N/M - Not Meaningful TOTAL SALES: VOLUME, PRICE, EXCHANGE
------------------------------------------------- YTD `03 % CHG. VOL PX FX ----------------------------------------------------------------------------------- TOTAL SALES $26,670 7% -2 7 2 ------- --- --- -- -- Total Pharmaceutical Sales 11,263 12% 6 1 5 ------- --- --- -- -- U.S. 6,823 8% 6 2 0 Foreign 4,440 18% 7 -1 12 -------------------------- Other Medco Sales 15,407 3% ---------------------------------------------------------
Exhibit 99.2 MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES SECOND QUARTER 2003 ================================================================================ OTHER (INCOME)/EXPENSE, NET
--------------------------------------------------- 2Q `03 2Q `02 YTD 2003 YTD 2002 ------------------------------------------------------------------------------------------------- INTEREST INCOME $ (82.6) $ (105.5) $ (170.9) $ (203.9) INTEREST EXPENSE 94.6 97.5 189.9 192.8 EXCHANGE (GAINS)/LOSSES (16.3) 5.3 (23.4) 2.6 MINORITY INTERESTS 40.6 59.9 92.4 110.6 AMORTIZATION OF INTANGIBLES 60.5 51.0 115.3 102.4 Other, net (195.4) (10.9) (242.6) (63.3) --------------------------------------------------- TOTAL $ (98.6) $ 97.3 $ (39.3) $ 141.2 -------------------------------------------------------------------------------------------------
================================================================================ JOINT VENTURE SALES DETAIL All sales reported here are end-market JV sales, presented on a "NET" basis.
--------------------------------------------------- MERIAL 2Q `03 2Q `02 YTD 2003 YTD 2002 ------------------------------------------------------------------------------------------------- IVOMEC, HEARTGARD, other avermectins $ 114 $ 121 $ 211 $ 220 FRONTLINE 170 142 302 262 Biologicals 98 97 200 184 Other Animal Health 50 47 96 92 Poultry Genetics 21 41 76 78 --------------------------------------------------- TOTAL MERIAL SALES $ 453 $ 448 $ 885 $ 836 -------------------------------------------------------------------------------------------------
--------------------------------------------------- AVENTIS PASTEUR-MSD 2Q `03 2Q `02 YTD 2003 YTD 2002 ------------------------------------------------------------------------------------------------- HEPATITIS VACCINES $ 19 $ 17 $ 37 $ 30 VIRAL VACCINES 13 9 24 16 Other Vaccines 114 81 204 150 --------------------------------------------------- TOTAL AP-MSD SALES $ 146 $ 107 $ 265 $ 196 -------------------------------------------------------------------------------------------------
--------------------------------------------------- MERCK / SCHERING-PLOUGH COLLABORATION 2Q `03 2Q `02 YTD 2003 YTD 2002 ------------------------------------------------------------------------------------------------- Zetia (Worldwide) $ 123 $ - $ 169 $ - TOTAL $ 123 $ - $ 169 $ - -------------------------------------------------------------------------------------------------
================================================================================ TOTAL MEDCO PRESCRIPTION/CLAIMS VOLUME (IN MILLIONS)
-------------------------------------- 2003 MAIL RETAIL TOTAL ------------------------------------------------------------------------------------ FIRST QUARTER 20 113 133 SECOND QUARTER 19 112 131 -------------------------------------- YEAR TO DATE 39 226 265 ------------------------------------------------------------------------------------
-------------------------------------- 2002 MAIL RETAIL TOTAL ------------------------------------------------------------------------------------ FIRST QUARTER 20 121 141 SECOND QUARTER 21 119 140 -------------------------------------- YEAR TO DATE 41 239 280 ------------------------------------------------------------------------------------